Thilo Schroeder - Feb 12, 2020 Form 3/A - Amendment Insider Report for Revolution Medicines, Inc. (RVMD)

Role
Director
Signature
/s/ Darren DeStefano, Attorney-in-Fact
Stock symbol
RVMD
Transactions as of
Feb 12, 2020
Transactions value $
$0
Form type
3/A - Amendment
Date filed
3/4/2022, 04:53 PM
Date Of Original Report
Feb 12, 2020
Next filing
Mar 4, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RVMD Series B Preferred Stock Feb 12, 2020 Common Stock 1.57M By Nextech V Oncology S.C.S., SICAV-SIF F1, F2, F3
holding RVMD Series C Preferred Stock Feb 12, 2020 Common Stock 549K By Nextech V Oncology S.C.S., SICAV-SIF F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 3 amendment is being filed to correct the original Form 3 filed on February 12, 2020. The Series B Preferred Stock and Series C Preferred Stock were omitted from the original filing.
F2 Each share of Series B Preferred Stock and Series C Preferred Stock will automatically convert into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
F3 Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.